Apollo Endosurgery Inc
NASDAQ:APEN
Intrinsic Value
Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of APEN.
Apollo Endosurgery Inc's market capitalization is 475.5m USD.
APEN stock price is 10 USD.
APEN.
APEN. Open DCF Valuation
APEN. Open Relative Valuation
APEN.
APEN's D/E (Debt to Equity) is equal to 1.04.
APEN's Revenue has grown by an exceptional 22% over the past 12 months.
APEN's long-term assets (110m USD) exceed its long-term liabilties (78m USD).
APEN's ROE (Return on Equity) has significantly decreased in the last 3 years from 1 211% to -85%.
APEN's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -36% to -69%, and is approaching profitability.
APEN's Revenue is forecast to grow at a rate of 34% per year over the next 3 years.
APEN has negative Net Debt. This means that the company has more cash and short-term investments (57m USD) than debt (34m USD).
APEN has negative Operating Income for the last twelve months.
APEN has negative Net Income for the last twelve months.
APEN's ROE (Return on Equity) for the past 12 months is negative and is equal to -85%.
APEN's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -69%.
APEN's short-term assets (93m USD) exceed its short-term liabilties (40m USD).
APEN has positive Gross Profit for the last twelve months.
APEN has negative Free Cash Flow for the last twelve months.
APEN has negative three-year average ROE (Return on Equity): -119%. The company is not efficient at transforming stockholders' equity into net income.
APEN has negative three-year average ROIC (Return on Invested Capital): -54%. The company is not efficient at using invested capital to generate operating income.
APEN's Altman Z-Score is very low and is equal to -0.8.
APEN doesn't generate enough operating income (-28m USD) to safely cover interest payments on its debt (3m USD).
Fundamental Analysis
Apollo Endosurgery Inc
Balance Sheet Decomposition
Apollo Endosurgery Inc
| Current Assets | 92.9m |
| Cash & Short-Term Investments | 57m |
| Receivables | 15m |
| Other Current Assets | 20.9m |
| Non-Current Assets | 17.4m |
| PP&E | 7.5m |
| Intangibles | 8.4m |
| Other Non-Current Assets | 1.4m |
| Current Liabilities | 39.5m |
| Accounts Payable | 7.4m |
| Accrued Liabilities | 12.4m |
| Other Current Liabilities | 19.7m |
| Non-Current Liabilities | 38.1m |
| Long-Term Debt | 34m |
| Other Non-Current Liabilities | 4.1m |
Earnings Waterfall
Apollo Endosurgery Inc
|
Revenue
|
76.9m
USD
|
|
Cost of Revenue
|
-34.4m
USD
|
|
Gross Profit
|
42.4m
USD
|
|
Operating Expenses
|
-70.2m
USD
|
|
Operating Income
|
-27.8m
USD
|
|
Other Expenses
|
-12m
USD
|
|
Net Income
|
-39.8m
USD
|
Free Cash Flow Analysis
Apollo Endosurgery Inc
What is Free Cash Flow?
APEN Profitability Score
Profitability Due Diligence
Apollo Endosurgery Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
Score
Apollo Endosurgery Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
APEN Solvency Score
Solvency Due Diligence
Apollo Endosurgery Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Apollo Endosurgery Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
APEN Price Targets Summary
Apollo Endosurgery Inc
Ownership
APEN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
APEN Price
Apollo Endosurgery Inc
| Average Annual Return | 49.78% |
| Standard Deviation of Annual Returns | 82.1% |
| Max Drawdown | -68% |
| Market Capitalization | 475.5m USD |
| Shares Outstanding | 47 549 200 |
| Percentage of Shares Shorted | 1.14% |
APEN News
Last Important Events
Apollo Endosurgery Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Apollo Endosurgery Inc
Company Profile
Apollo Endosurgery Inc
Country
Industry
Market Cap
Dividend Yield
Description
Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. The company is headquartered in West Lake Hills, Texas and currently employs 107 full-time employees. The company went IPO on 2005-04-21. The firm develops and distributes devices that are used by surgeons and gastroenterologists for various procedures related to gastrointestinal conditions including closure of gastrointestinal defects, managing gastrointestinal complications and the treatment of obesity. The firm's products include the OverStitch Endoscopic Suturing System, which enables advanced endoscopic procedures from within the Gastrointestinal tract, or endolumenally, by allowing physicians to suture, especially full-thickness, and secure the approximation of tissue. The X-Tack Endoscopic HeliX Tacking System is a suture-based device designed specifically for closing and healing defects in the lower gastrointestinal tract. The Orbera Intragastric Balloon System is a non-surgical alternative for interventional weight loss.
You don't have any saved screeners yet
